Mumbai, 7th August 2026: Fermenta Biotech Limited, one of the world’s largest manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutritional ingredients, green chemistry, APIs and customized food premixes, today announced the successful listing of its equity shares on the National Stock Exchange of India Limited (NSE).
Effective 4 August 2026, the Company’s 2,94,30,987 equity shares, of face value ₹5 each, have been listed and admitted to dealings on the NSE under the symbol FERMENTA and ISIN INE225B01021. The Company’s equity shares will continue to remain listed on the BSE under Scrip Code 506414.
The milestone was commemorated through a ceremonial bell-ringing event held at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex. Present were representatives from NSE, Fermenta’s Board and senior leadership team, and other stakeholders.
The listing marks a milestone in Fermenta’s 75-year journey. Founded in 1951 and listed on the BSE since 1977, the Company has grown from its pharmaceutical and biotechnology foundations into a globally recognised manufacturer serving customers in more than 60 countries, anchored by decades of technical expertise and backed by rigorous global compliance standards and certifications.
Listed on the BSE since 1977, Fermenta’s NSE listing reflects the Company’s growth, expanding global customer base and widening investor interest. It provides access to shareholders and market participants across both major Indian stock exchanges, supporting broader participation, improved visibility and more efficient price discovery.
Comment from Prashant Nagre, Managing Director: “Fermenta’s listing on the NSE represents a significant milestone in a landmark year for the Company, as we commemorate 75 years of Fermenta and nearly five decades as a publicly listed enterprise, alongside important recognitions in food safety and workplace culture. It reflects a journey shaped by resilience and a path forward defined by innovation, scale and focus. We will continue to enhance our capabilities across nutrition, food fortification, green chemistry and specialised solutions.
The NSE listing further strengthens our capital-market presence and reaffirms our commitment to transparency, responsible governance and consistent engagement with shareholders. We extend our sincere appreciation to our promoters, Board, shareholders, employees, customers, partners and all other stakeholders for their continued confidence in Fermenta.”
Mr. Krishna Datla, Executive Vice Chairman (Fermenta Biotech Limited),
Mr. Krishnan Iyer, Head – Issuer Relationship (NSE),
Mr. Prashant Nagre, Managing Director (Fermenta Biotech Limited),
Mr. Satish Varma, Executive Director (Fermenta Biotech Limited)
